

---

*primary studies - congress abstract*

## **Effects of tezacaftor/ivacaftor (TEZ/IVA) treatment in patients with cystic fibrosis and F508del/F508del-CFTR: patient-reported outcomes in a Phase 3, randomised, controlled trial (EVOLVE)**

**Code:** CN-XXXXX013    **Year:** 2019    **Date:** 2019

**Author:** Sommerburg O

### **See also**

Pneumologie (Stuttgart, Germany), 2019, 73(SUPPL. 1)

### **Keywords**

Adult; Aged; CFTR Modulators; Genetic Predisposition to Disease; pharmacological\_intervention; placebo; VX-770; VX-661; ivacaftor; Aminophenols; tezacaftor; VX-445; Symdeko; Symkevi;